Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by
progressive lung scarring and the histological picture of usual interstitial pneumonia (UIP). It …

Background Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease
characterized by the aberrant accumulation of fibrotic tissue in the lungs parenchyma …

Rationale: Nintedanib and pirfenidone slow the progression of idiopathic pulmonary fibrosis
(IPF), but the disease continues to progress. More data are needed on the safety and …

Since December 2019, coronavirus disease (COVID‐19) has rapidly swept the world. So far,
more than 30 million people have been infected and nearly one million have died. Although …

Background Idiopathic pulmonary fibrosis, a progressive and inevitably fatal disorder, has a
highly variable clinical course. Biomarkers that reflect disease activity are urgently needed to …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung
disease (ILD) of unknown aetiology, with a median survival of 2–4 years from the time of …

Background Accumulation of profibrotic myofibroblasts in fibroblastic foci (FF) is a crucial
process for development of fibrosis during idiopathic pulmonary fibrosis (IPF) pathogenesis …

Rationale: Since their approval, there has been no real-world or randomized trial evidence
evaluating the effect of the antifibrotic medications pirfenidone and nintedanib on clinically …

Background The assessment of treatment response in idiopathic pulmonary fibrosis (IPF) is
complicated by the variable clinical course. We examined the variability in the rate of …

Background The prevalence of idiopathic pulmonary fibrosis (IPF) is increasing every year.
Pirfenidone and nintedanib were approved for treatment of IPF in 2014, but they received …